SLT versus daily latanoprost to lower eye pressure in early to moderate open‑angle glaucoma and ocular hypertension

Selective Laser Trabeculoplasty Versus Latanoprost as First Line Treatments for Primary Open-angle Glaucoma and Ocular Hypertension: A Comparative Analysis

This trial will test whether a one‑time selective laser trabeculoplasty (SLT) or daily 0.005% latanoprost eye drops better lower eye pressure in treatment‑naïve adults with early to moderate primary open‑angle glaucoma or ocular hypertension.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 138 (estimated)
• Ages: 18 Years to 90 Years
• Sex: All
• Sponsor: Lagos State Health Service Commission (Academic / other)
• Locations: 1 site (Ikeja, Lagos)
• Trial ID: NCT07310719 on ClinicalTrials.gov

What this trial studies

This observer‑masked, randomized controlled trial at Lagos State University Teaching Hospital will assign treatment‑naïve adults with early to moderate primary open‑angle glaucoma or ocular hypertension to either SLT or 0.005% latanoprost drops. A total of 138 eyes (69 per group) will be followed over 12 months to compare short‑term intraocular pressure (IOP) lowering, safety, and patient‑reported quality of life. Clinical assessments include serial IOP measurements, optic nerve imaging, visual field testing, and monitoring for adverse events, with observers masked to treatment assignment. The primary analysis will compare mean IOP reduction between groups and report differences in side effects and quality‑of‑life outcomes.

Who should consider this trial

Good fit: Adults aged 18 or older who are newly diagnosed, treatment‑naïve with early to moderate primary open‑angle glaucoma or ocular hypertension and average IOP >21 mmHg who can give informed consent.

Not a fit: Patients with prior glaucoma treatment, advanced glaucoma, secondary or congenital glaucoma, or corneal opacity that prevents proper evaluation are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, this could offer a one‑time laser option that lowers eye pressure as effectively as daily drops and reduce the burden of lifelong eyedrop use.

How similar studies have performed: Large trials in other populations (for example the UK LiGHT trial) have shown SLT can be as effective as prostaglandin drops, though data specifically from Nigerian patients are limited.

Eligibility criteria

Inclusion Criteria:

1. Patients aged 18years and above.
2. Patients newly diagnosed as Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
3. Patients with elevated IOP greater than 21mmHg (average of 3 measurements taken on 3 different clinic visits).
4. Patients categorized as early or moderate glaucoma POAG (cup -disc ratio 0.5 to 0.7, visual field analysis MD - 6dB to -12dB and disc damage likelihood score (DDLS) 5 to 7) on funduscopy, Optical coherence tomography, and fundus photograph
5. Patients who agree to participate in the study after informed consent.

Exclusion Criteria:

1. A prior medical, surgical, or laser treatment for glaucoma
2. Patients diagnosed with primary congenital glaucoma or secondary glaucoma
3. Advanced glaucoma (CDR greater than 0.8, visual field analysis MD more than -12dB and DDLS stage 8 and above)
4. Patients with cloudy cornea or corneal opacity that would impair the view of the anterior chamber angles, fundus, or give false IOP readings
5. Patients with media opacity, such as cataracts, vitreous haze, or vitreous hemorrhage that prevents examination of the posterior segment.
6. Patients who have undergone previous ocular surgeries (cataract surgery, trabeculectomy).
7. Patients with a history of ocular trauma or uveitis
8. Pregnant and lactating women.

   \-

Where this trial is running

Ikeja, Lagos

• Lagos State University teaching Hospital Eye Institute — Ikeja, Lagos, Nigeria (Recruiting)

Study contacts

• Study coordinator: Anne I. Abang-Obi, MBBS

Conditions Primary Open Angle Glaucoma or Ocular Hypertension; Selective laser trabeculoplasty